BackgroundAims: The use of HAART in pregnancy has shown remarkable improvement in immune status and have revolutionized the approach of care to people living with HIV. Some adverse pregnancy conditions have been reported which may depend on type of regimen, time and duration of use. The use of ARVs in pregnancy have been dynamic and transition from one regimen to the other have setting and country based variations. Therefore, knowing the impact of ARVs in pregnancy among PLHIV in our settings deserve evidence based information.MethodsPregnant women attending antenatal clinic at the hospital were prospectively recruited and followed up. HIV positive mothers were recruited irrespective of gestation age. At the time of delivery, obstetric and neonatal characteristics were entered into computer database. Mothers and their children were followed until 6 weeks postpartum. The data was analyzed with Epi-info version 7.1.5. Chi square at significant level of 0.05 and confidence level of 95% was used to determine significance.ResultsA total of 55 HIV positive mothers were in the study. The age range was between 18 to 45 years and parity was 0 to 8. The mean birth weight and gestation age at delivery was 2.92 kg (SD 0.556) and 36 weeks (SD 2.8 weeks) respectively. The absolute CD4 count of 350cells/mm3 and above (57.13%) was associated with low incidence of low birth weight. The mean glycaemic results were within normal range, 4.02–4.75 and 5.00-6.79 Mmol/l pre and post prandial respectively.Conclusionlow birth weight was not associated with HAART in pregnancy and good immune condition was not associated any low birth weight. There was no association of protease inhibitors and gestational diabetes mellitus